Treating What We Could Have Prevented: The Trillion-Dollar Trap at the Center of American Healthcare

Somewhere in the arithmetic of American healthcare lies a contradiction so stark it borders on institutional negligence. Each year, the United States spends well over $4 trillion on health-related costs. A conservative estimate from the Centers for Disease Control and Prevention suggests that approximately 90 percent of that expenditure goes toward managing chronic conditions — the majority of which are, to a significant degree, preventable. Meanwhile, public health agencies, community prevention programs, and the infrastructure of early intervention receive a fraction of that investment, consistently underfunded and politically undervalued.

This is not a new observation. Researchers, public health advocates, and policy analysts have documented the imbalance for decades. And yet the ratio has not meaningfully shifted. The question worth asking — the one this investigation attempts to answer — is not merely whether we are making the wrong choices, but why the wrong choices have become so thoroughly institutionalized.

The Numbers Behind the Imbalance

Consider diabetes. The American Diabetes Association estimated in its most recent economic analysis that the total cost of diagnosed diabetes in the United States exceeds $327 billion annually, encompassing direct medical costs as well as lost productivity. Type 2 diabetes, which accounts for the vast majority of cases, is widely understood to be preventable — or at minimum, significantly delayable — through lifestyle interventions involving modest dietary adjustments and increased physical activity.

The landmark Diabetes Prevention Program, a federally funded clinical trial, demonstrated that structured lifestyle interventions reduced the incidence of type 2 diabetes by 58 percent among high-risk adults. The cost of delivering that intervention: roughly $1,400 per participant over the course of the study. The average annual cost of managing a diagnosed diabetic patient in the United States currently exceeds $16,750.

The arithmetic is not ambiguous. And yet the CDC's National Diabetes Prevention Program, which scales this intervention through community partners, serves only a small fraction of the estimated 96 million American adults with prediabetes. Awareness remains low, referrals from physicians are inconsistent, and insurance reimbursement — though improving — is still far from universal.

Heart disease tells a similar story. It remains the leading cause of death in the United States, accounting for roughly one in every five fatalities. The economic burden exceeds $200 billion annually. High blood pressure, elevated cholesterol, physical inactivity, and smoking — the primary modifiable risk factors — are all addressable through preventive interventions that cost a fraction of the cardiac procedures, hospitalizations, and long-term medications that follow when those risk factors go unmanaged.

Why Treatment Wins, Structurally

Understanding why prevention remains underfunded requires looking past individual behavior and examining the structural incentives that govern how money flows through the American healthcare system.

The dominant model of healthcare reimbursement in the United States is fee-for-service: providers are compensated for procedures, tests, and treatments delivered. A cardiologist who performs a stent placement generates revenue. A primary care physician who spends thirty minutes counseling a patient on dietary changes and prescribing a structured exercise program generates comparatively little — if anything beyond a modest office visit fee. The system, in its design, rewards intervention after illness more generously than it rewards the work of preventing illness from occurring.

Pharmaceutical and medical device industries, which represent some of the most powerful lobbying forces in Washington, have obvious financial interests in a treatment-oriented system. A drug that manages a chronic condition indefinitely is, from a revenue standpoint, more valuable than a public health campaign that prevents that condition from developing. This is not a conspiracy — it is a market logic operating precisely as markets are designed to operate. The problem is that market logic and public health logic are not always aligned.

Insurance structures compound the issue. Preventive care investments made today yield health returns over a horizon of five, ten, or twenty years. But Americans change insurers with considerable frequency — through job changes, income fluctuations, and policy renewals. An insurer that invests in a member's long-term prevention may not be the insurer that ultimately avoids the cost of that member's future hospitalization. The financial incentive to invest in prevention is therefore diluted across the industry.

The Underfunding of Public Health Infrastructure

Beyond clinical care, the broader public health infrastructure — the agencies, community organizations, and local health departments responsible for population-level prevention — has faced sustained disinvestment for decades. Even before the COVID-19 pandemic exposed the fragility of this system, public health funding as a share of overall health spending had been declining. The pandemic prompted emergency investment, but much of that has since lapsed, and local health departments across the country continue to operate with reduced staffing and constrained budgets.

This matters because many of the most effective prevention strategies are not clinical — they are environmental and social. Safe walkable neighborhoods encourage physical activity. Access to fresh, affordable food reduces the risk of diet-related chronic disease. Early childhood nutrition programs, workplace wellness initiatives, and community-based health education all generate measurable health returns. These are not glamorous line items in a federal budget. They do not generate the kind of acute, visible outcomes that command political attention. But the evidence for their effectiveness is substantial and growing.

Realigning Incentives: What a Prevention-First Economy Could Look Like

The path toward a healthcare economy that genuinely prioritizes prevention is not a mystery. The policy levers are well understood, even if the political will to pull them has been inconsistent.

Value-based care models — which tie provider reimbursement to patient health outcomes rather than service volume — represent one of the most promising structural reforms. When a physician's compensation is linked to whether her patients maintain healthy blood pressure or avoid preventable hospitalizations, the calculus around time spent on counseling and early intervention changes meaningfully. Several large health systems and payer networks have moved in this direction, with encouraging early results.

Expanding insurance coverage mandates for evidence-based preventive services, including structured lifestyle interventions for high-risk individuals, would lower the financial barriers that currently discourage participation. The Affordable Care Act took important steps in this direction by requiring coverage of recommended preventive services without cost-sharing, though implementation has been uneven and ongoing legal challenges have created uncertainty.

Perhaps most critically, sustained and adequate investment in public health infrastructure — at the federal, state, and local levels — is essential. Prevention cannot be delivered exclusively through clinical encounters. It requires the community-level programs, health education systems, and environmental policies that create the conditions for healthy behavior at scale.

The Cost of Continuing to Wait

The economic argument for prevention is, at this point, overwhelming. So is the moral argument. A healthcare system that spends billions treating conditions it could have prevented for a fraction of the cost is not, in any meaningful sense, a health system. It is an illness management system — one that has confused its purpose with its revenue model.

The Prevention Project has long held that genuine health equity requires not just access to treatment, but access to the tools, environments, and investments that make illness less likely in the first place. That vision is not utopian. It is, in fact, the more fiscally responsible path — and the one that the evidence has consistently pointed toward.

What remains is a question of institutional will: whether the structures that govern American healthcare can be realigned, incrementally or otherwise, with the goals they nominally serve. The data suggests we cannot afford to keep waiting for the answer.